Swiss pharma giants Roche and Novartis fight over patent in US court
Roche claims there was a patent infringement on the lung drug Esbriet.
Copyright 2016 The Associated Press. All Rights Reserved.
This content was published on
1 minute
Keystone-SDA/ds
Swiss pharmaceutical giant Roche is taking its rival Novartis to court in the US. Roche subsidiary Genentech has filed suit in New Jersey District Court against Novartis subsidiary Sandoz for patent infringement on the lung drug Esbriet.
This is according to the indictment filed on Monday, cited by the Keystone-SDA news agency. The case was first reported by Reuters.
Genentech complains that Sandoz started selling a generic version of Esbriet in mid-May 2022, even though Sandoz had not applied for a license. As a result, Genentech’s patent had been infringed, it said. The generic displacement of Esbriet has caused significant financial harm to the Roche subsidiary, it said. Esbriet had sales of more than $740 million (CHF650 million) in the U.S. alone in 2021.
Genentech is now seeking unspecified damages including lost profits and/or an appropriate royalty. Sandoz is also expected to pay the legal costs.
Genentech’s Esbriet is used to treat idiopathic pulmonary fibrosis (IPF), a fatal chronic lung disease with no cure. Roche earned over $1 billion worldwide from Esbriet in 2021, but sales fell to under $820 million in 2022, according to Reuters.
Popular Stories
More
Workplace Switzerland
What lies ahead for Switzerland: an economic outlook for 2025
Have you heard something about Swiss diplomacy that you’d like us to fact check?
Not all information circulating about Switzerland’s foreign relations is accurate or well understood. Tell us what you'd like us to fact check or clarify.
This content was published on
After the emergency landing of a SWISS aircraft in Graz last week, inquiries have detected a “previously unknown fault pattern” in an engine.
Appeals filed against new Rottweiler ban in Zurich
This content was published on
Authorities in Zurich say they have received several appeals against a new ban on Rottweilers starting on January 1, 2025.
Record number of start-ups founded in Switzerland in 2024
This content was published on
Almost 53,000 start-ups were registered in 2024, up from 51,500 the previous year, the Institut für Jungunternehmen (IFJ) said on Tuesday.
Russian ambassador praises Swiss openness for dialogue
This content was published on
Sergei Garmonin says Swiss willingness to keep communications channels open is “noticeably better than in a number of other Western countries”.
Swiss researchers help to pinpoint 200-year-old volcanic eruption
This content was published on
Scientists have finally discovered which volcano was behind an 1831 eruption that impacted climate and crops across the world.
SNB stayed out of FX markets despite third-quarter franc rally
This content was published on
The Swiss National Bank again refrained from significantly influencing the franc in the third quarter of 2024, even as the currency saw a rally.
SWISS crew member dies in Graz after emergency landing
This content was published on
One week after the emergency landing of a Swiss International Air Lines plane in Austria, a crew member has died in hospital.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis seals deal to license high-priced cancer drug
This content was published on
Swiss pharma giant Novartis has finalised a deal to allow generic production of its patented drug nilotinib to treat chronic myeloid leukemia.
This content was published on
Switzerland takes the top spot in total patent filings per capita to the European Patent Office. Roche and ABB lead the field among Swiss companies.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.